Clinical trial NCT06124976: Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
Official title: A Phase 2/3 Multicenter Trial Evaluating the Safety and Efficacy of ST-02 (Mucoadhesive Gemcitabine Suspension) on Ablation of Urothelial Carcinomas in the Upper Urinary Tract
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Urothelial Carcinoma of the Renal Pelvis and Ureter
Transitional Cell Cancer of the Renal Pelvis and Ureter
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2023-11-09
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this prospective clinical trial is to investigate the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to treat Upper Tract Urothelial Carcinoma (UTUC) in participants who have a low-grade tumor.

The main questions this study aims to answer are:

1. Can ST-02 effectively eradicate UTUC by 3 months?
2. Is ST-02 safe for patients with UTUC?

Participants in this study will receive ST-02, a new formulation with gemcitabine once weekly for six weeks. Gemcitabine is known to be an effective drug in treating urothelial carcinoma. This new formulation will be instilled directly into the upper urinary tract (renal pelvis) and will allow the chemotherapeutic to work locally for an extended period of time. The administration process will be retrograde (via a small catheter inserted up into the kidney, under anesthesia) or antegrade (via a nephrostomy, in the clinic) once weekly for six weeks. Safety and efficacy will be monitored for up to a year after the initial response assessment.

Detailed description: This study is a prospective, multicenter, single-arm, open-label clinical trial assessing the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to chemo-ablate low-grade urothelial carcinoma of the upper urinary tract.

Participants with biopsy confirmed low-grade (LG) upper tract urothelial carcinoma (UTUC) and a tumor of 5 to 15 mm will receive 6 weekly instillations of ST-02.

The primary objective is to evaluate complete response (CR) at 3 months from the first instillation during the primary tumor evaluation (PTE) visit. This is done by ureteroscopy, and cytology, with or without biopsy if a tumor remains. If the participant presents as a CR, they will receive their first maintenance instillation of ST-02. Endoscopic monitoring of the upper tract with ureteroscopy for responders will be performed every 3 months for up to 12 months after CR, and the patient will receive a single instillation of ST-02 if no recurrence is noted each time.

Participants who do not have a CR will be treated by their physician with the standard of care, such as biopsy and laser ablation, and with any additional surgical procedure or treatment as deemed necessary by the Principal Investigator (PI).

The first stage of the trial will enroll 30 patients. If there are 8 or fewer CR among these 30 participants, the study will be stopped. Otherwise, an additional 40 participants will be accrued into phase 3, resulting in a total sample size of 70.

The durability of response, event-free survival, safety, and other outcomes will also be measured.

Eligibility criteria: Inclusion Criteria:

* Adult (≥ 18 years) male or female
* Primary or recurrent low-grade (LG), noninvasive (Ta) Upper Tract Urothelial Carcinoma (UTUC) in the renal pelvis, infundibulum, and/or calyces, based on ureteroscopy, biopsy and cytology performed within 8 weeks prior to the Screening Visit
* At least 1 measurable papillary tumor measuring 5-15 mm
* Low grade tumor(s) in the ipsilateral ureter. Every attempt should be made to ablate this tumor completely, but residual ipsilateral ureteral tumor is not an exclusion criterion.
* Prior fully ablated low grade bladder tumor(s), without the need for intravesical therapy except for single-dose chemotherapy
* A life expectancy of greater than 12 months
* No active untreated urinary tract infection (UTI) as confirmed by urine culture or urinalysis
* Women of Child bearing potential (WoCBP) and Males who have a WoCBP partner require a negative pregnancy test at the Screening visit and must use two acceptable contraceptives methods until six months post-treatment
* All sexually active males must agree to use a condom during intercourse, for at least 48 h after each instillation

Exclusion Criteria:

* Have received Bacillus Calmette - Guerin (BCG) treatment for UTUC within 6 weeks prior to Visit 1
* Pregnant (positive urine pregnancy test), planning pregnancy during trial, breast-feeding, or of childbearing potential without reliable contraception
* Unresolved infection requiring active treatment with systemic antimicrobial drugs
* History of high-grade non-muscle invasive bladder cancer within the past 6 months
* History of muscle-invasive bladder cancer during the past 2 years
* Actively being treated or intend to be treated with intravesical or systemic chemotherapy during the duration of the trial
* Urinary obstruction in the ipsilateral Upper Urinary Tract (UUT)
* Any contraindicated to gemcitabine or sensitivity to gemcitabine or any of the ST-02 ingredients
* Currently receiving another investigational agent or involved in a clinical trial with an investigational product within the past 30 days prior to Visit 1
* Active hepatitis B (chronic or acute) or active hepatitis C infection

Primary outcomes:
measure: Complete Response (CR) rate at the Primary Tumor Evaluation (PTE) visit
timeFrame: 3 months
Secondary outcomes:
measure: Durable efficacy
timeFrame: 12 months after CR
measure: Objective Response Rate (ORR)
timeFrame: 3 months
measure: Event-Free Survival (EFS)
timeFrame: 15 months
measure: Number of adverse event
timeFrame: 15 months
measure: Peak Plasma Concentration (Cmax)
timeFrame: 24 hours
measure: Pharmacokinetics (Tmax)
timeFrame: 24 hours
measure: Rate of invasive surgery
timeFrame: 15 months
measure: Clinical impact of PR in not endoscopically resectable UTUC
timeFrame: 3 months
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Vancouver Prostate Centre
state: British Columbia
city: Halifax
country: Canada
facility: Centre of Applied Urology Research, Nova Scotia Health Authority
state: Nova Scotia
city: Toronto
country: Canada
facility: UHN - Princess Margaret Cancer Centre
state: Ontario
Study officials:
affiliation: Vancouver Prostate Centre
name: Peter Black, Dr.
role: PRINCIPAL_INVESTIGATOR
References: